Content
All Posts > Content under Pharma/Biotech
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
Article By:
ChinaBio® Today
Read
Sunday, November 3, 2019 1:34 AM EDT
BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By:
Benzinga
Read
Friday, November 1, 2019 7:38 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
IBI Market Insight: To Profit From Value Disconnect
Article By:
Dr. Hung Tran
Read
Wednesday, October 30, 2019 2:11 PM EDT
Precision medicine therapeutics and companion diagnostics are powering the next wave of innovation.
Cannabis 2.0: Canopy Growth Introduces 16 New Ways To Get High - Stock Remains Subdued
Article By:
Lorimer Wilson
Read
Wednesday, October 30, 2019 11:39 AM EDT
Canopy Growth unveiled a list of 16 new marijuana-infused drink and edible products yesterday (Tuesday) as its initial foray into the Canadian Cannabis 2.0 marketplace.
Reata Pharmaceuticals, Inc. (RETA): These Hedge Funds Sold Prior To Large Gains
Article By:
Insider Monkey
Read
Wednesday, October 30, 2019 10:18 AM EDT
Judging by the fact that Reata Pharmaceuticals, Inc. has faced falling interest from the aggregate hedge fund industry, it’s easy to see that there lies a certain “tier” of fund managers that slashed their positions entirely heading into Q3.
In this article: RETA
Week In Review: Suzhou's Ascentage Pharma Stages $53 Million IPO In Hong Kong
Article By:
ChinaBio® Today
Read
Saturday, October 26, 2019 9:04 PM EDT
Deals, financings, trials and approvals, and other company news for Chinese companies involved in global biotech.
Healthcare & Biotechs Struggle, But Opportunity Ahead
Article By:
Tarun Chandra, CFA
Read
Wednesday, October 23, 2019 2:24 AM EDT
Improving risk appetite is nudging markets higher, and biotechs will participate as well, although gains will have a ceiling.
In this article: ACAD, ARQL, MNTA, SGEN, MDCO, ARWR, KPTI, RDUS, FLXN, RETA, ZYME, DRNA, TCDA, DCPH, APLS, ACHN, ALXN, VRTX, ALDR, RARX, DOVA
No Memorial Today
Article By:
Vivian Lewis
Read
Tuesday, October 22, 2019 11:55 PM EDT
Our sold stocks are crashing and our bought stocks climbing! We have reports from the USA, Japan, Israel, Denmark, and Canada, and that's only about pharmaceuticals. We also have exciting news about lung cancer, but some bad news from India...
In this article: BMY, NVO, ESALY, GNCGY, NPSNY, BIIB, INFY, TEVA, ZYME, PROSY, EC, SLB, SQM, CMDXF, JMPLY, ITRN, LBTYA, LBTYK, CZZ, TMRAF, SAN, ANFGF, AZSEY, ACAT, CBBYF
Week In Review: Taimei Raises $212 Million For AI Life Science Support Software
Article By:
ChinaBio® Today
Read
Sunday, October 20, 2019 4:00 AM EDT
Deals, financings, trials and approvals in the China bio markets over the past week.
Week In Review: Jiangsu's CTFH Signs $200 Million AI Drug Discovery Pact With Insilico
Article By:
ChinaBio® Today
Read
Saturday, October 12, 2019 6:12 PM EDT
Jiangsu's CTFH Pharma formed a partnership worth up to $200 million with Insilico Medicine, which will use its AI technology to discover two triple-negative breast cancer candidates.